https://www.selleckchem.com/pr....oducts/fasoracetam-n
inib therapy, the median PFS was 7.9 months (95%CI 4.1-11.7 months). Among the 15 patients with brain metastasis, the median PFS was 6.0 months (95%CI 2.2-9.8 months). The main toxicities related to pyrotinib were diarrhea in 57 (79.2%) cases, and 48 (66.7%) cases with grade 1-2 as well as 9 (12.5%) cases with grade 3. CONCLUSION Pyrotinib based therapy is an effective treatment for patients with HER2 positive MBC, including patients with lapatinib treatment failure and brain metastasis, and the toxicities can be tolerated.OB
Aimer
Commentaire
Partagez
